We are live on ! Find out more
DNLI icon

Denali Therapeutics
DNLI

222 hedge funds and large institutions have $1.85B invested in Denali Therapeutics in 2025 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 74 increasing their positions, 81 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more call options, than puts

Call options by funds: $848K | Put options by funds: $515K

4.71% more ownership

Funds ownership: 88.89% → 93.6% (+4.7%)

3% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 34

0% less funds holding

Funds holding: 223 → 222 (-1)

9% less repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 81

29% less capital invested

Capital invested by funds: $2.61B → $1.85B (-$758M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
222
Holders Change
-1
Holders Change %
-0.45%
% of All Funds
2.98%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
35
Increased
74
Reduced
81
Closed
34
Calls
$848K
Puts
$515K
Net Calls
+$333K
Net Calls Change
-$267K

Top Buyers

1
UBS AM
UBS AM
Illinois
+$61M
2
Norges Bank
Norges Bank
Norway
+$38M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$29.9M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$25.1M
5
Millennium Management
Millennium Management
New York
+$20.9M

Top Sellers

1
CCM
Camber Capital Management
Massachusetts
-$19.2M
2
Capital Research Global Investors
Capital Research Global Investors
California
-$13.6M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$11.6M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$11.2M
5
PAMP
Polar Asset Management Partners
Ontario, Canada
-$10.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
First Trust Advisors
226
First Trust Advisors
Illinois
– -$1.33M -65,442 Closed
DP
227
Diadema Partners
New Jersey
– -$1.22M -60,000 Closed
AG
228
Algert Global
California
– -$795K -39,015 Closed
FRM
229
Fox Run Management
Connecticut
– -$788K -38,668 Closed
Los Angeles Capital Management
230
Los Angeles Capital Management
California
– -$453K -22,222 Closed
UOC
231
UBS O'Connor
Illinois
– -$429K -21,039 Closed
BC
232
BIT Capital
Germany
– -$428K -21,011 Closed
BPC
233
Bryce Point Capital
New York
– -$419K -20,550 Closed
CM
234
Caption Management
Oklahoma
– -$406K -19,900 Closed
BHCM
235
Brevan Howard Capital Management
Jersey
– -$365K -17,917 Closed
Ameriprise
236
Ameriprise
Minnesota
– -$341K -16,743 Closed
BG
237
Bellevue Group
Switzerland
– -$320K -15,700 Closed
ACM
238
Aquatic Capital Management
Illinois
– -$320K -15,694 Closed
VPIM
239
Vanguard Personalized Indexing Management
California
– -$232K -11,377 Closed
PD
240
Point72 (DIFC)
United Arab Emirates
– -$152K -7,438 Closed
PHK
241
Point72 Hong Kong
Hong Kong
– -$64.7K -3,175 Closed
VEA
242
Virtus ETF Advisers
New York
– -$61.7K -3,029 Closed
RS
243
R Squared
Hong Kong
– -$11.8K -580 Closed
OC
244
Oarsman Capital
Wisconsin
– -$10.2K -500 Closed
PWMG
245
Private Wealth Management Group
New Jersey
– -$5.3K -260 Closed
BIG
246
Brooklyn Investment Group
New York
– -$3.51K -172 Closed
MAM
247
Meeder Asset Management
Ohio
– -$3.36K -165 Closed
AWM
248
Activest Wealth Management
Florida
– -$2.51K -131 Closed
AAP
249
Arax Advisory Partners
Colorado
– -$2.38K -117 Closed
Bessemer Group
250
Bessemer Group
New Jersey
– -$2K -110 Closed
7 8 9
10
11

DNLI Hedge Fund Activity: Q1 2025 in Review

222 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q1 2025, worth a combined $1.85B — down 29% from $2.61B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new DNLI positions and 34 closed out — a net gain of 1 holder — while 74 added to existing stakes and 81 trimmed.

The largest buyer was UBS AM, adding an estimated $61M. The largest seller was Camber Capital Management, cutting an estimated $19.2M.

  • 222 institutional investors held Denali Therapeutics (DNLI) as of Q1 2025, down from 223 in Q4 2024.
  • Funds reported $1.85B of Denali Therapeutics stock for Q1 2025, down 29% quarter-over-quarter.
  • 35 funds opened new Denali Therapeutics positions in Q1 2025 and 34 closed out, a net change of +1 holder.
  • The largest Denali Therapeutics buyer in Q1 2025 was UBS AM, an estimated $61M added.
  • The largest Denali Therapeutics seller in Q1 2025 was Camber Capital Management, an estimated $19.2M sold.

Based on aggregated 13F filings for Q1 2025.